The Use of Functional Magnetic Resonance Imaging to Test Pharmacotherapies for Alcohol Use Disorder: A Systematic Review

Overview

Journal Alcohol Clin Exp Res

Specialty Psychiatry

Date 2019 Aug 7

PMID 31386215

Citations 15

Authors

Erica N Grodin

Lara A Ray

Affiliations

Soon will be listed here.

Abstract

Alcohol use disorder (AUD) is a chronic relapsing condition that represents a significant public health concern. Pharmacological treatment development for AUD is a top research priority, and many studies are being conducted to evaluate potential AUD treatments. Understanding the brain circuitry impacted by addiction is crucial for the development of efficacious pharmacological interventions. These neuroadaptations can be probed noninvasively using functional magnetic resonance neuroimaging (fMRI). fMRI may be an effective tool to identify biomarkers for AUD pharmacotherapies, evaluating changes associated with pharmacological treatment. Thus, the present qualitative review of the literature focuses on the role of fMRI as a tool for medication development for AUD. The aim of this review was to assemble research across a range of fMRI paradigms to study the effectiveness of pharmacological treatments of adult AUD. First, we present a qualitative review of fMRI AUD pharmacotherapy studies, differentiating studies based on their dosing regimen. Second, we provide recommendations for the field to improve the use of fMRI as a biomarker for AUD pharmacotherapy.

Citing Articles

Comparative effects of topiramate and naltrexone on neural activity during anticipatory anxiety in individuals with alcohol use disorder.

Dali G, Logge W, Kranzler H, Hurzeler T, Gallagher H, Haber P Alcohol Alcohol. 2024; 60(1).

PMID: 39558663 PMC: 11573881. DOI: 10.1093/alcalc/agae078.

The neurobehavioural effects of cannabidiol in alcohol use disorder: Study protocol for a double-blind, randomised, cross over, placebo-controlled trial.

Hurzeler T, Logge W, Watt J, DeMayo M, Suraev A, McGregor I Contemp Clin Trials Commun. 2024; 41:101341.

PMID: 39252861 PMC: 11382041. DOI: 10.1016/j.conctc.2024.101341.

The effects of N-acetyl cysteine on intrinsic functional connectivity and neural alcohol cue reactivity in treatment-seeking individuals with alcohol use disorder: a preliminary study.

Logge W, Haber P, Hurzeler T, Towers E, Morley K Psychopharmacology (Berl). 2024; 242(1):149-160.

PMID: 39102049 PMC: 11742866. DOI: 10.1007/s00213-024-06656-z.

Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder.

Belnap M, McManus K, Grodin E, Ray L Pharmaceut Med. 2024; 38(4):291-302.

PMID: 38967906 PMC: 11272707. DOI: 10.1007/s40290-024-00526-x.

The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action.

Tap S Addict Biol. 2024; 29(4):e13386.

PMID: 38600715 PMC: 11007263. DOI: 10.1111/adb.13386.

References

Bach P, Weil G, Pompili E, Hoffmann S, Hermann D, Vollstadt-Klein S . Incubation of neural alcohol cue reactivity after withdrawal and its blockade by naltrexone. Addict Biol. 2019; 25(1):e12717. DOI: 10.1111/adb.12717. View

Hermann D, Smolka M, Wrase J, Klein S, Nikitopoulos J, Georgi A . Blockade of cue-induced brain activation of abstinent alcoholics by a single administration of amisulpride as measured with fMRI. Alcohol Clin Exp Res. 2006; 30(8):1349-54. DOI: 10.1111/j.1530-0277.2006.00174.x. View

Schmaal L, Goudriaan A, Joos L, Dom G, Pattij T, van den Brink W . Neural substrates of impulsive decision making modulated by modafinil in alcohol-dependent patients. Psychol Med. 2014; 44(13):2787-98. DOI: 10.1017/S0033291714000312. View

Ray L, Bujarski S, Yardley M, Roche D, Hartwell E . Differences between treatment-seeking and non-treatment-seeking participants in medication studies for alcoholism: do they matter?. Am J Drug Alcohol Abuse. 2017; 43(6):703-710. PMC: 6159933. DOI: 10.1080/00952990.2017.1312423. View

Hoge R, Atkinson J, Gill B, Crelier G, Marrett S, Pike G . Linear coupling between cerebral blood flow and oxygen consumption in activated human cortex. Proc Natl Acad Sci U S A. 1999; 96(16):9403-8. PMC: 17795. DOI: 10.1073/pnas.96.16.9403. View

Schwandt M, Cortes C, Kwako L, George D, Momenan R, Sinha R . The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects. Neuropsychopharmacology. 2016; 41(12):2818-2829. PMC: 5061889. DOI: 10.1038/npp.2016.61. View

Heeger D, Ress D . What does fMRI tell us about neuronal activity?. Nat Rev Neurosci. 2002; 3(2):142-51. DOI: 10.1038/nrn730. View

Mukamel R, Gelbard H, Arieli A, Hasson U, Fried I, Malach R . Coupling between neuronal firing, field potentials, and FMRI in human auditory cortex. Science. 2005; 309(5736):951-4. DOI: 10.1126/science.1110913. View

Buxton R, Uludag K, Dubowitz D, Liu T . Modeling the hemodynamic response to brain activation. Neuroimage. 2004; 23 Suppl 1:S220-33. DOI: 10.1016/j.neuroimage.2004.07.013. View

10.

Norberg M, Krystal J, Tolin D . A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008; 63(12):1118-26. DOI: 10.1016/j.biopsych.2008.01.012. View

11.

MacKillop J . The Behavioral Economics and Neuroeconomics of Alcohol Use Disorders. Alcohol Clin Exp Res. 2016; 40(4):672-85. PMC: 4846981. DOI: 10.1111/acer.13004. View

12.

Schacht J, Anton R, Myrick H . Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review. Addict Biol. 2012; 18(1):121-33. PMC: 3419322. DOI: 10.1111/j.1369-1600.2012.00464.x. View

13.

Lukas S, Lowen S, Lindsey K, Conn N, Tartarini W, Rodolico J . Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study. Neuroimage. 2013; 78:176-85. DOI: 10.1016/j.neuroimage.2013.03.055. View

14.

Agabio R, Sinclair J, Addolorato G, Aubin H, Beraha E, Caputo F . Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry. 2018; 5(12):957-960. DOI: 10.1016/S2215-0366(18)30303-1. View

15.

Logothetis N . The underpinnings of the BOLD functional magnetic resonance imaging signal. J Neurosci. 2003; 23(10):3963-71. PMC: 6741096. View

16.

Ray L, Chin P, Miotto K . Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol Disord Drug Targets. 2010; 9(1):13-22. DOI: 10.2174/187152710790966704. View

17.

Beck A, Pelz P, Lorenz R, Charlet K, Geisel O, Heinz A . Effects of high-dose baclofen on cue reactivity in alcohol dependence: A randomized, placebo-controlled pharmaco-fMRI study. Eur Neuropsychopharmacol. 2018; 28(11):1206-1216. DOI: 10.1016/j.euroneuro.2018.08.507. View

18.

Holla B, Karthik S, Biswal J, Viswanath B, Jayarajan D, Bharath R . Brain Functional Magnetic Resonance Imaging Cue-reactivity Can Predict Baclofen Response in Alcohol Use Disorders. Clin Psychopharmacol Neurosci. 2018; 16(3):290-301. PMC: 6124881. DOI: 10.9758/cpn.2018.16.3.290. View

19.

Logge W, Morris R, Baillie A, Haber P, Morley K . Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berl). 2019; 238(5):1291-1302. DOI: 10.1007/s00213-019-05192-5. View

20.

Spierling S, Zorrilla E . Don't stress about CRF: assessing the translational failures of CRFantagonists. Psychopharmacology (Berl). 2017; 234(9-10):1467-1481. PMC: 5420464. DOI: 10.1007/s00213-017-4556-2. View